Upstream Bio Inc

UPB

8.670USD

-1.120-11.44%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Upstream Bio Inc's Score

Industry at a Glance

Industry Ranking

48 / 391

Overall Ranking

150 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Upstream Bio Inc Highlights

StrengthsRisks

Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 19.92% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.85M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.85M.

Overvalued

The company’s latest PE is -3.25, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 50.20M shares, increasing 0.90% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 117.00 shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

44.167

Target Price

+351.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Upstream Bio Inc is 6.42, ranking 249 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 668.00K, representing a year-over-year increase of 8.97%, while its net profit experienced a year-over-year increase of 94.86%.

Score

Industry at a Glance

Previous score

6.42

Change

0



Financials

8.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.81

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Upstream Bio Inc is 6.75, ranking 224 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.25, which is -1.79% below the recent high of -3.20 and -520.83% above the recent low of -20.21.

Score

Industry at a Glance

Previous score

6.75

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Upstream Bio Inc is 8.25, ranking 146 out of 391 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 75.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.25

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Upstream Bio Inc is 7.15, ranking 76 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.32 and the support level at 7.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.06

Change

-1.91

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Upstream Bio Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 92.89%, representing a quarter-over-quarter decrease of 1.53%. The largest institutional shareholder is The Vanguard, holding a total of 2.38M shares, representing 4.41% of shares outstanding, with 160.94% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.69M

+7.45%

OrbiMed Advisors, LLC

5.69M

--

Access Industries, Inc.

5.49M

--

Decheng Capital LLC

3.29M

--

Norges Bank Investment Management (NBIM)

969.92K

-3.01%

Enavate Sciences GP, LLC

2.46M

--

The Vanguard Group, Inc.

Star Investors

2.17M

+139.34%

BlackRock Institutional Trust Company, N.A.

1.84M

+71.30%

HBM Partners AG

2.72M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Upstream Bio Inc is 4.93, ranking 59 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Upstream Bio Inc

UPB

7.19 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment